Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression

Core Tip

Core Tip: Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM), both components of metabolic syndrome, are increasingly recognized for their synergistic impact on cardiovascular health. The intertwined relationship between these conditions amplifies the risk of cardiovascular disease, highlighting the need for integrated management strategies to mitigate this dual threat. Through a comprehensive evaluation of Cernea et al’s study on the combination of MASLD and T2DM in promoting cardiac dysfunction, this editorial provides a comprehensive review of the current research on MASLD and cardiovascular disease, a discussion of the progress made in this field, and the potential directions for future research.